135 related articles for article (PubMed ID: 16076236)
1. Affordability of medicines and patients' cost-reducing behaviour: empirical evidence based on SUR estimates from Italy and the UK.
Atella V; Schafheutle E; Noyce P; Hassell K
Appl Health Econ Health Policy; 2005; 4(1):23-35. PubMed ID: 16076236
[TBL] [Abstract][Full Text] [Related]
2. Access to medicines: cost as an influence on the views and behaviour of patients.
Schafheutle EI; Hassell K; Noyce PR; Weiss MC
Health Soc Care Community; 2002 May; 10(3):187-95. PubMed ID: 12121255
[TBL] [Abstract][Full Text] [Related]
3. Cost to the patient or cost to the healthcare system? Which one matters the most for GP prescribing decisions? A UK-Italy comparison.
Hassell K; Atella V; Schafheutle EI; Weiss MC; Noyce PR
Eur J Public Health; 2003 Mar; 13(1):18-23. PubMed ID: 12678309
[TBL] [Abstract][Full Text] [Related]
4. European healthcare policies for controlling drug expenditure.
Ess SM; Schneeweiss S; Szucs TD
Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
[TBL] [Abstract][Full Text] [Related]
5. Patients' intention to consume prescribed and non-prescribed medicines: A study based on the theory of planned behaviour in selected European countries.
Kamekis A; Bertsias A; Moschandreas J; Petelos E; Papadakaki M; Tsiantou V; Saridaki A; Symvoulakis EK; Souliotis K; Papadakis N; Faresjö T; Faresjö A; Martinez L; Agius D; Uncu Y; Sengezer T; Samoutis G; Vlcek J; Abasaeed A; Merkouris B; Lionis C
J Clin Pharm Ther; 2018 Feb; 43(1):26-35. PubMed ID: 28833330
[TBL] [Abstract][Full Text] [Related]
6. Mental health care and out-of-pocket expenditures in Europe: results from the ESEMeD project.
Sevilla-Dedieu C; Kovess-Masfety V; Gilbert F; Vilagut G; Koenig HH; Bruffaerts R; Haro JM; Alonso J
J Ment Health Policy Econ; 2011 Jun; 14(2):95-105. PubMed ID: 21881165
[TBL] [Abstract][Full Text] [Related]
7. Patients' views on the UK policy of prescription charges-Insights from qualitative interviews.
Schafheutle EI
Res Social Adm Pharm; 2008 Dec; 4(4):343-54. PubMed ID: 19064241
[TBL] [Abstract][Full Text] [Related]
8. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1091-9. PubMed ID: 18942671
[TBL] [Abstract][Full Text] [Related]
9. The cost of prescription medicines to patients.
Noyce PR; Huttin C; Atella V; Brenner G; Haaijer-Ruskamp FM; Hedvall M; Mechtler R
Health Policy; 2000 Jun; 52(2):129-45. PubMed ID: 10794841
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Changes in Cost Sharing on the Consumption of Prescription and Over-the-Counter Medicines in Catalonia.
Martínez-Jiménez M; García-Gómez P; Puig-Junoy J
Int J Environ Res Public Health; 2021 Mar; 18(5):. PubMed ID: 33806543
[TBL] [Abstract][Full Text] [Related]
11. A research roadmap for complementary and alternative medicine - what we need to know by 2020.
Fischer F; Lewith G; Witt CM; Linde K; von Ammon K; Cardini F; Falkenberg T; Fønnebø V; Johannessen H; Reiter B; Uehleke B; Weidenhammer W; Brinkhaus B
Forsch Komplementmed; 2014; 21(2):e1-16. PubMed ID: 24851850
[TBL] [Abstract][Full Text] [Related]
12. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
13. Osteoarthritis in Europe: impact on health status, work productivity and use of pharmacotherapies in five European countries.
Kingsbury SR; Gross HJ; Isherwood G; Conaghan PG
Rheumatology (Oxford); 2014 May; 53(5):937-47. PubMed ID: 24489012
[TBL] [Abstract][Full Text] [Related]
14. Financial Burden of Prescribed Medicines Included in Outpatient Benefits Package Schemes: Comparative Analysis of Co-Payments for Reimbursable Medicines in European Countries.
Vogler S; Dedet G; Pedersen HB
Appl Health Econ Health Policy; 2019 Dec; 17(6):803-816. PubMed ID: 31506879
[TBL] [Abstract][Full Text] [Related]
15. Australia's pharmaceutical cost sharing policy: reducing waste or affordability?
Doran E; Robertson J
Aust Health Rev; 2009 May; 33(2):231-40. PubMed ID: 19563311
[TBL] [Abstract][Full Text] [Related]
16. A conceptually based approach to understanding chronically ill patients' responses to medication cost pressures.
Piette JD; Heisler M; Horne R; Caleb Alexander G
Soc Sci Med; 2006 Feb; 62(4):846-57. PubMed ID: 16095789
[TBL] [Abstract][Full Text] [Related]
17. Social inequalities and pharmaceutical cost sharing in Italian regions.
Terraneo M; Sarti S; Tognetti Bordogna M
Int J Health Serv; 2014; 44(4):761-85. PubMed ID: 25626227
[TBL] [Abstract][Full Text] [Related]
18. Improving the Affordability of Prescription Medications for People with Chronic Respiratory Disease. An Official American Thoracic Society Policy Statement.
Patel MR; Press VG; Gerald LB; Barnes T; Blake K; Brown LK; Costello RW; Crim C; Forshag M; Gershon AS; Goss CH; Han MK; Lee TA; Sweet S; Gerald JK
Am J Respir Crit Care Med; 2018 Dec; 198(11):1367-1374. PubMed ID: 30601674
[TBL] [Abstract][Full Text] [Related]
19. Affordability Assessment from a Static to Dynamic Concept: A Scenario-Based Assessment of Cardiovascular Medicines.
Zarei L; Karimzadeh I; Moradi N; Peymani P; Asadi S; Babar ZU
Int J Environ Res Public Health; 2020 Mar; 17(5):. PubMed ID: 32151039
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
